GLP-1 RAs to assist with weight loss have exploded in popularity. Researchers are working to identify which patients will ...

Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / November ...

Findings were published today in The Lancet Diabetes & Endocrinology. Originally developed to treat diabetes, GLP-1 receptor agonists mimic the action of a hormone called glucagon-like peptide 1, ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

On November 18, at the American Heart Association (AHA) 100th Annual Meeting 2024, the safety of glucagon-like peptide-1 ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

GLP-1 medications like Ozempic and Wegovy have skyrocketed in popularity ... it's not a crisis if you forget to pack it or ...

Lexaria Bioscience (LEXX) announced that dosing has been completed for human pilot study #3 investigating a DehydraTECH-processed version of ...